Association between transfusion of whole blood and recurrence of cancer NEIL BLUMBERG, JOANNA M HEAL, PAUL MURPHY, MUKESH M AGARWAL, CHRISTY CHUANG Abstract Transfusion affects the immune response to renal transplantation and may be associated with recurrence of various human neoplasms. Data from patients with colonic, rectal, cervical, and prostate tumours showed an association between transfusion of any amount of whole blood or larger amounts of red blood cells at the time of surgery and later recurrence of cancer. Recipients of one unit of whole blood had a significantly higher incidence of recurrence (45%) than recipients of a single unit ofred cells (12%) (p=0-03). Recipients of two units of whole blood also had a higher rate of recurrence (52%) than those receiving two units of red cells (23%) (p=0-03). Recipients of any amount of whole blood had similar recurrence rates (38-52%). Recipients of four or more units of red blood cells had a higher rate of recurrence (55%) than those receiving three or fewer units of red blood cells (20%) (p=0005). Mortality due to cancer in patients receiving three or fewer units of red blood cells (2%) was similar to that in patients who did not have transfusions (7%) and significantly lower than that observed in patients receiving three or fewer units of whole blood (20%) (p=0O003). A proportional hazards risk analysis showed that transfusion of any whole blood or more than three units of red blood cells was significantly associated with earlier recurrence and death due to cancer.
These data support an association between transfusion and recurrence of cancer. They also suggest that some factor present in greater amounts in whole blood, such as plasma, may contribute to the increased risk of recurrence in patients who have undergone transfusion. Until the questions raised by retrospective studies of cancer recurrence and transfusion can be answered by prospective interventional trials with washed red blood cells, red blood cells should be transfused to patients with cancer in preference to whole blood when clinically feasible.
Introduction
A growing body of data shows that blood transfusions have immunological effects on patients and experimental animals beyond those of alloimmunisation to blood cell antigens. [1] [2] [3] The best characterised clinical consequence is that of improved renal allograft survival in transfused patients compared with that in those not receiving homologous blood. These findings have led to studies on whether transfusion at the time of cancer surgery might be associated with immunological modulation of the patient and unfavourable rates of tumour recurrence. The first study showing such an adverse relation was that of Burrows and Tartter on patients with colonic cancer,4 which has been followed by numerous studies documenting associations between perioperative transfusion and poorer outcome in patients with cancers of the colon and rectum, 6 lung,7" breast,9 and cervix," as well as soft tissue sarcomas." Some studies have failed to find such associations or have found small differences that are not significant. '2 18 Furthermore, almost all studies have been retrospective reviews of medical records, subject to many biases, raising the possibility that the reported associations are due to unfavourable prognostic factors that are in turn linked to the likelihood of transfusion. 2 The failure of some studies to confirm an association between tumour recurrence and transfusion may be due to local factors of cancer biology'9 or treatment strategies or to the absence of a causal relation. Because transfusion practices vary greatly between clinicians and hospitals we hypothesised that differences in the kind of blood components transfused might have some bearing on the findings in different studies. Our own study of recurring colorectal tumours found a dramatic association between tumour recurrence and transfusion. A dose-response relation between number of transfusions and tumour recurrence, however, could not be discerned. This was surprising if an immunological mechanism analogous to that seen in renal allograft survival exists. A doseresponse relation between the number of transfusions and renal allograft survival has been clearly shown.' Thus we analysed our data on patients who had undergone transfusion who had cancer of the colon, rectum, cervix,' and prostate to see if differences in the amount and kind of transfusions were associated with varying recurrence and death rates.
Patients and methods
The methods used to collect data on patients with cervical and prostate cancer were identical with those reported in our retrospective study ofcolonic and rectal tumours.I In brief, the names and identifying numbers ofhospital patients seen between 1970 and 1982 with these diagnoses were retrieved from a computerised database and the medical record reviewed, collecting a variety of demographic, clinical, and treatment data. Transfusion data were also confirmed from blood bank records. Patients were included in the study if (16, 8) , (19, 6) for the transfusion group and (6,3), (18, 5) , (44, 11) for the control group. The proportion of the transfusion group who had recurrences or died because of cancer was significantly higher than that of the control group, except those with cervical cancer. The trends for recurrence and death reported by kind and amount of blood transfused were similar for each tumour. A breakdown of the data by tumour is available from the authors.
We initially thought that whole blood transfusions might be associated with a greater risk of recurrence and death due to cancer than red blood cell transfusions. Table I shows data for incidence of recurrence and mortality for all of the cancer patients who had had transfusions. The data are stratified according to whether whole blood or red blood cells were given and the number of transfusions received. Differences in incidence of recurrence and mortality due to cancer observed among patients receiving one or two units of whole blood and those receiving the corresponding number of red blood 
STATISTICAL ANALYSIS
The methods detailed in our previous paper on colonic and rectal cancer were used. 5 We used x2 statistics to compare the transfusion and control groups with respect to the various prognostic factors. 20 We also used such statistics to compare the incidence of recurrence or death in the various groups defined by the variables under study. These latter analyses were followed by statistical techniques that allow adjustment for differences in prognostic factors. (fig 1) . We therefore studied 361 women, who~had a Rh positive child. Table I -shows the pertinent clinical data on these women.-All women on whom genetic amniocentesis wasperformed were followed ujp with a questionnaire filled in by the hospital where delivery took place.
Besides stating, complcations occurring during pregnancy and delivery and after birth the q'uestionnaire gave the rhesus state of the mother and child and information on whether immunopropbiylaxis had been administered to
